Alternative Gingival De-Epithelialization Techniques
Launched by UNIVERSITY OF MICHIGAN · Jul 12, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Participants will be randomly assigned to one of four surgical techniques during their surgical procedure and the wound site will be assessed on post-operative days 1, 7, 14, and 21.
Researchers will compare the use of mucotome, Er:YAG laser, surgical diamond bur, or blade to observe patterns of wound healing and assess if one method is superior in terms of removing the epithelium.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists (ASA) Physical Status Classification I or II
- • Subjects undergoing periodontal surgical procedures that involve harvesting of soft tissue samples, who have a treatment plan including the use or removal of keratinized mucosa or subepithelial connective tissue that will not require additional anesthesia for sample collection
- • Adequate physical and mental health to undergo routine dental treatment
- • Ability and willingness to follow instructions related to the study procedures
- Exclusion Criteria:
- • Poorly controlled diabetes, defined as HbA1c \>/= 7.0
- • Autoimmune or inflammatory conditions such as systemic lupus erythematous, rheumatoid arthritis.
- • Pregnant women or nursing mothers, or unsure of pregnancy status (self-reported)
- • Severe hematologic disorders, such as leukemia or hemophilia
- • Subjects on anticoagulant or antiplatelet therapy
- • Local or systemic infection that may interfere with healing
- • Hepatic or renal diseases
- • Currently under cancer treatment or within 18 months from completion of radio- or chemotherapy
- • History of antibiotic or immunosuppressant use in the last 3 months
- • Subjects on concomitant drug therapy for systemic conditions that may affect outcomes of the study
- • Current smokers (CDC definition): heavy smokers: subjects who have smoked \>10 cigarettes per day within 6 months of study onset, and have smoked \>100 cigarettes in their lifetime
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Sandra Stuhr, DMD, MS
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported